CXCR4 and cancer: Our results support a vast body of literature that validates CXCR4 as a promising target for cancer therapy and demonstrate that small-molecule CXCR4 antagonists have novel therapeutic potential for HIV infection beyond their activity against viral entry by blocking Nef induced T-cell depletion.